In a significant vote of confidence for peptide-based medicine, biopharmaceutical giant Gilead Sciences has announced a licensing deal worth $1.3 billion upfront to secure rights to an experimental oral peptide developed by PepStar. The peptide targets interleukin-23 (IL-23), a protein involved in several inflammatory and autoimmune conditions, and is designed to compete with existing injectable biologics in this therapeutic space.
What makes this development particularly exciting for the peptide field is the oral delivery format. IL-23 inhibitors have traditionally been delivered via injection, requiring patients to administer or receive shots on a regular schedule. An effective oral peptide alternative could offer a more convenient treatment option for patients managing chronic inflammatory conditions, potentially improving treatment adherence and quality of life.
This deal also reflects the broader momentum building behind oral peptide technology as a scientific discipline. Historically, peptides have faced challenges with oral bioavailability due to degradation in the digestive system, which is why injectable formulations have dominated this class of therapeutics. Major pharmaceutical investments like this one suggest that advances in peptide engineering and formulation science are successfully overcoming these longstanding hurdles.
Gilead’s substantial upfront commitment signals strong institutional confidence in both the specific molecule and the underlying oral peptide platform technology. Such investments often accelerate further research and development, potentially paving the way for additional oral peptide candidates targeting other therapeutic areas in the future. As the peptide therapeutics landscape continues to evolve, partnerships of this scale help validate the scientific and commercial viability of this approach.
This article is for informational purposes only and does not constitute medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Source: Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde – Fierce Biotech
Leave a Reply